Intensity Therapeutics Doses First U.S. Patient in Phase 3 Study for Metastatic Sarcoma Treatment

Proactive - Interviews for investors

Intensity Therapeutics CEO Lew Bender joined Steve Darling from Proactive to announce a significant milestone: the first U.S. patient has been dosed in the company's pivotal Phase 3 clinical trial for treating metastatic sarcoma. This global superiority study is designed to evaluate the efficacy of INT230-6, a novel therapeutic agent, as a monotherapy compared to the investigator's choice of three standard-of-care systemic chemotherapy drugs. The trial focuses on second or third-line treatment for patients with metastatic, recurrent, or inoperable soft tissue sarcomas (STS). Bender highlighted that the Phase 3 trial aims to enroll approximately 333 patients worldwide, with the primary endpoint being overall survival. The study is structured so that for every three patients enrolled, two will receive INT230-6, and one will receive the current standard of care. The trial specifically targets STS subtypes including leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. This Phase 3 study follows promising data from Intensity Therapeutics' earlier Phase 1/2 trial, where INT230-6 demonstrated significant tumor-killing and immune-activating properties, leading to increased survival rates in patients with metastatic disease. Soft tissue sarcoma is a rare and challenging type of cancer that originates in the body's soft tissues, such as muscles, fat, blood vessels, nerves, tendons, and the linings of joints. The disease most commonly affects the arms, legs, and abdomen. In the United States, approximately 197,000 patients are living with sarcoma, which encompasses more than 50 different subtypes. Initial treatment typically involves surgery, but the recurrence or metastasis of the disease often necessitates additional therapeutic approaches, underscoring the importance of new treatment options like INT230-6. #proactiveinvestors #intensitytherapeuticsinc #nasdaq #ints #CancerTreatment #IntensityTherapeutics #LewBender #Phase3Trial #Sarcoma #BreastCancer #InnovativeTherapy #Immunotherapy #Oncology #Biotech#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews